Everolimus in Patients with Previously Treated Metastatic Neuroendocrine Tumors (NETs)

#659

Introduction: Everolimus is the standard of care in well-differentiated NETs. Previous randomized trials included patients treated with a maximum of two lines of prior chemotherapy. We evaluated everolimus in heavily pretreated patients with NETs.

Aim(s): To evaluate efficacy and tolerability of everolimus in previously treated patients with NETs.

Materials and methods: Seventeen patients with NETs were treated with everolimus 10 mg q.d. All patients received long-acting octreotide. The mean age was 53 years (25-71), three male, 14 female. The main primary tumor site was pancreas – nine patients (53%). Nine patients had 0-1-2 prior lines of chemotherapy and eight patients were heavily pretreated with more than three lines of chemotherapy.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Gorbunova V, Orel N, Kuzminov A, Markovich A, Odintsova A,

Keywords: neuroendocrine tumor, everolimus,